Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain

Iryna Khasabova, Michelle Holman, Tim Morse, Natalya Burlakova, Lia Coicou, Catherine A Harding-Rose, Donald A Simone, Virginia S. Seybold

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Opioids do not effectively manage pain in many patients with advanced cancer. Because anandamide (AEA) activation of cannabinoid type-1 receptors (CB1R) on nociceptors reduces nociception, manipulation of AEA metabolism in the periphery may be an effective alternative or adjuvant therapy in the management of cancer pain. AEA is hydrolyzed by the intracellular enzyme fatty acid amide hydrolase (FAAH), and this enzyme activity contributes to uptake of AEA into neurons and to reduction of AEA available to activate CB1R. We used an in vitro preparation of adult murine dorsal root ganglion (DRG) neurons co-cultured with fibrosarcoma cells to investigate how tumors alter the uptake of AEA into neurons. Evidence that the uptake of [3H]AEA into dissociated DRG cells in the co-culture model mimicked the increase in uptake that occurred in DRG cells from tumor-bearing mice supported the utility of the in vitro model to study AEA uptake. Results with the fluorescent AEA analog CAY10455 confirmed that an increase in uptake in the co-culture model occurred in neurons. One factor that contributed to the increase in [3H]AEA uptake was an increase in total cellular cholesterol in the cancer condition. Treatment with the FAAH inhibitor URB597 reduced CAY10455 uptake in the co-culture model to the level observed in DRG neurons maintained in the control condition (i.e., in the absence of fibrosarcoma cells), and this effect was paralleled by OMDM-1, an inhibitor of AEA uptake, at a concentration that had no effect on FAAH activity. Maximally effective concentrations of the two drugs together produced a greater reduction than was observed with each drug alone. Treatment with BMS309403, which competes for AEA binding to fatty acid binding protein-5, mimicked the effect of OMDM-1 in vitro. Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone. Intraplantar injection of OMDM-1 (5μg) into the tumor-bearing paw reduced mechanical hyperalgesia through a CB1R-dependent mechanism and also reduced a spontaneous nocifensive behavior. The same dose reduced withdrawal responses evoked by suprathreshold mechanical stimuli in naive mice. These data support the conclusion that OMDM-1 inhibits AEA uptake by a mechanism that is independent of inhibition of FAAH and provide a rationale for the development of peripherally restricted drugs that decrease AEA uptake for the management of cancer pain.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalNeurobiology of Disease
Volume58
DOIs
StatePublished - Oct 1 2013

Fingerprint

Hyperalgesia
Sensory Receptor Cells
Spinal Ganglia
Cannabinoid Receptors
Neurons
Coculture Techniques
Neoplasms
Fibrosarcoma
Pharmaceutical Preparations
Fatty Acid-Binding Proteins
Nociceptors
Injections
Nociception
Enzymes
Opioid Analgesics
anandamide
Cancer Pain
Therapeutics
Cholesterol
Bone and Bones

Keywords

  • Anandamide
  • CAY10455
  • Cancer
  • Dorsal root ganglion
  • Fatty acid amide hyrdolase
  • Fatty acid binding protein
  • Hydrolysis
  • Hyperalgesia
  • Neuron
  • Transport
  • URB597
  • Uptake

Cite this

Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. / Khasabova, Iryna; Holman, Michelle; Morse, Tim; Burlakova, Natalya; Coicou, Lia; Harding-Rose, Catherine A; Simone, Donald A; Seybold, Virginia S.

In: Neurobiology of Disease, Vol. 58, 01.10.2013, p. 19-28.

Research output: Contribution to journalArticle

Khasabova, Iryna ; Holman, Michelle ; Morse, Tim ; Burlakova, Natalya ; Coicou, Lia ; Harding-Rose, Catherine A ; Simone, Donald A ; Seybold, Virginia S. / Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. In: Neurobiology of Disease. 2013 ; Vol. 58. pp. 19-28.
@article{6ecc137d034e481b9e188e1efc274f40,
title = "Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain",
abstract = "Opioids do not effectively manage pain in many patients with advanced cancer. Because anandamide (AEA) activation of cannabinoid type-1 receptors (CB1R) on nociceptors reduces nociception, manipulation of AEA metabolism in the periphery may be an effective alternative or adjuvant therapy in the management of cancer pain. AEA is hydrolyzed by the intracellular enzyme fatty acid amide hydrolase (FAAH), and this enzyme activity contributes to uptake of AEA into neurons and to reduction of AEA available to activate CB1R. We used an in vitro preparation of adult murine dorsal root ganglion (DRG) neurons co-cultured with fibrosarcoma cells to investigate how tumors alter the uptake of AEA into neurons. Evidence that the uptake of [3H]AEA into dissociated DRG cells in the co-culture model mimicked the increase in uptake that occurred in DRG cells from tumor-bearing mice supported the utility of the in vitro model to study AEA uptake. Results with the fluorescent AEA analog CAY10455 confirmed that an increase in uptake in the co-culture model occurred in neurons. One factor that contributed to the increase in [3H]AEA uptake was an increase in total cellular cholesterol in the cancer condition. Treatment with the FAAH inhibitor URB597 reduced CAY10455 uptake in the co-culture model to the level observed in DRG neurons maintained in the control condition (i.e., in the absence of fibrosarcoma cells), and this effect was paralleled by OMDM-1, an inhibitor of AEA uptake, at a concentration that had no effect on FAAH activity. Maximally effective concentrations of the two drugs together produced a greater reduction than was observed with each drug alone. Treatment with BMS309403, which competes for AEA binding to fatty acid binding protein-5, mimicked the effect of OMDM-1 in vitro. Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone. Intraplantar injection of OMDM-1 (5μg) into the tumor-bearing paw reduced mechanical hyperalgesia through a CB1R-dependent mechanism and also reduced a spontaneous nocifensive behavior. The same dose reduced withdrawal responses evoked by suprathreshold mechanical stimuli in naive mice. These data support the conclusion that OMDM-1 inhibits AEA uptake by a mechanism that is independent of inhibition of FAAH and provide a rationale for the development of peripherally restricted drugs that decrease AEA uptake for the management of cancer pain.",
keywords = "Anandamide, CAY10455, Cancer, Dorsal root ganglion, Fatty acid amide hyrdolase, Fatty acid binding protein, Hydrolysis, Hyperalgesia, Neuron, Transport, URB597, Uptake",
author = "Iryna Khasabova and Michelle Holman and Tim Morse and Natalya Burlakova and Lia Coicou and Harding-Rose, {Catherine A} and Simone, {Donald A} and Seybold, {Virginia S.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.nbd.2013.04.018",
language = "English (US)",
volume = "58",
pages = "19--28",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain

AU - Khasabova, Iryna

AU - Holman, Michelle

AU - Morse, Tim

AU - Burlakova, Natalya

AU - Coicou, Lia

AU - Harding-Rose, Catherine A

AU - Simone, Donald A

AU - Seybold, Virginia S.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Opioids do not effectively manage pain in many patients with advanced cancer. Because anandamide (AEA) activation of cannabinoid type-1 receptors (CB1R) on nociceptors reduces nociception, manipulation of AEA metabolism in the periphery may be an effective alternative or adjuvant therapy in the management of cancer pain. AEA is hydrolyzed by the intracellular enzyme fatty acid amide hydrolase (FAAH), and this enzyme activity contributes to uptake of AEA into neurons and to reduction of AEA available to activate CB1R. We used an in vitro preparation of adult murine dorsal root ganglion (DRG) neurons co-cultured with fibrosarcoma cells to investigate how tumors alter the uptake of AEA into neurons. Evidence that the uptake of [3H]AEA into dissociated DRG cells in the co-culture model mimicked the increase in uptake that occurred in DRG cells from tumor-bearing mice supported the utility of the in vitro model to study AEA uptake. Results with the fluorescent AEA analog CAY10455 confirmed that an increase in uptake in the co-culture model occurred in neurons. One factor that contributed to the increase in [3H]AEA uptake was an increase in total cellular cholesterol in the cancer condition. Treatment with the FAAH inhibitor URB597 reduced CAY10455 uptake in the co-culture model to the level observed in DRG neurons maintained in the control condition (i.e., in the absence of fibrosarcoma cells), and this effect was paralleled by OMDM-1, an inhibitor of AEA uptake, at a concentration that had no effect on FAAH activity. Maximally effective concentrations of the two drugs together produced a greater reduction than was observed with each drug alone. Treatment with BMS309403, which competes for AEA binding to fatty acid binding protein-5, mimicked the effect of OMDM-1 in vitro. Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone. Intraplantar injection of OMDM-1 (5μg) into the tumor-bearing paw reduced mechanical hyperalgesia through a CB1R-dependent mechanism and also reduced a spontaneous nocifensive behavior. The same dose reduced withdrawal responses evoked by suprathreshold mechanical stimuli in naive mice. These data support the conclusion that OMDM-1 inhibits AEA uptake by a mechanism that is independent of inhibition of FAAH and provide a rationale for the development of peripherally restricted drugs that decrease AEA uptake for the management of cancer pain.

AB - Opioids do not effectively manage pain in many patients with advanced cancer. Because anandamide (AEA) activation of cannabinoid type-1 receptors (CB1R) on nociceptors reduces nociception, manipulation of AEA metabolism in the periphery may be an effective alternative or adjuvant therapy in the management of cancer pain. AEA is hydrolyzed by the intracellular enzyme fatty acid amide hydrolase (FAAH), and this enzyme activity contributes to uptake of AEA into neurons and to reduction of AEA available to activate CB1R. We used an in vitro preparation of adult murine dorsal root ganglion (DRG) neurons co-cultured with fibrosarcoma cells to investigate how tumors alter the uptake of AEA into neurons. Evidence that the uptake of [3H]AEA into dissociated DRG cells in the co-culture model mimicked the increase in uptake that occurred in DRG cells from tumor-bearing mice supported the utility of the in vitro model to study AEA uptake. Results with the fluorescent AEA analog CAY10455 confirmed that an increase in uptake in the co-culture model occurred in neurons. One factor that contributed to the increase in [3H]AEA uptake was an increase in total cellular cholesterol in the cancer condition. Treatment with the FAAH inhibitor URB597 reduced CAY10455 uptake in the co-culture model to the level observed in DRG neurons maintained in the control condition (i.e., in the absence of fibrosarcoma cells), and this effect was paralleled by OMDM-1, an inhibitor of AEA uptake, at a concentration that had no effect on FAAH activity. Maximally effective concentrations of the two drugs together produced a greater reduction than was observed with each drug alone. Treatment with BMS309403, which competes for AEA binding to fatty acid binding protein-5, mimicked the effect of OMDM-1 in vitro. Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone. Intraplantar injection of OMDM-1 (5μg) into the tumor-bearing paw reduced mechanical hyperalgesia through a CB1R-dependent mechanism and also reduced a spontaneous nocifensive behavior. The same dose reduced withdrawal responses evoked by suprathreshold mechanical stimuli in naive mice. These data support the conclusion that OMDM-1 inhibits AEA uptake by a mechanism that is independent of inhibition of FAAH and provide a rationale for the development of peripherally restricted drugs that decrease AEA uptake for the management of cancer pain.

KW - Anandamide

KW - CAY10455

KW - Cancer

KW - Dorsal root ganglion

KW - Fatty acid amide hyrdolase

KW - Fatty acid binding protein

KW - Hydrolysis

KW - Hyperalgesia

KW - Neuron

KW - Transport

KW - URB597

KW - Uptake

UR - http://www.scopus.com/inward/record.url?scp=84878496660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878496660&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2013.04.018

DO - 10.1016/j.nbd.2013.04.018

M3 - Article

VL - 58

SP - 19

EP - 28

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -